ASAndreia Silva

Andreia Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreia Silva has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?

    by Raquel Pinto, Centro Hospitalar Tondela-Viseu Serviço de Nefrologia, Carolina Ferreira, André Ferreira, Joaquim Milheiro, Catarina Veiga, Maria Costa, Andreia Silva, Carla Lima, Sérgio Lemos, et al.

  • Open Access

    Case report: rivaroxaban related nephropathy

    by Luisa Lemos Costa, Ana Rodrigues, Raquel Pinto, Carla Lima, Tânia Sousa, Helena Viana, Mário Góis, Sérgio Lemos, Andreia Silva

    The characteristics of direct oral anticoagulants (DOACs) make them more appealing for prevention of thromboembolic events than vitamin K antagonists (VKA). Despite that, both classes have been a recognized as a cause of anticoagulant related nephropathy (ARN). Herein we describe a case of a 72-year-old man, with chronic kidney disease (CKD), medicated with rivaroxaban, who presented with acute kidney injury (AKI) and microscopic hematuria. The kidney biopsy revealed anticoagulant related-nephropathy. Rivaroxaban was suspended, the patient showed improvement of renal function and apixaban was prescribed. This case emphasizes the need for careful monitoring of serum creatinine when these drugs are prescribed, especially in high risk groups.


  • Open Access

    Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center

    by Cristiana Maximiano, Andreia Silva, Inês Duro, Tiago Branco, Liane Correia-Costa, Ana Teixeira, Liliana Rocha, Teresa Costa, Paula Matos, Maria Do Sameiro Faria, et al.

    Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterizedby the triadof microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, which primarily affects preschool-aged children. This study's aim was to describe the clinical profile, management, and long-term outcome of the genetic aHUS patients admitted to a tertiary care pediatric nephrology center during 20 years. Methods: We performed a retrospective analysis of the clinical records of all aHUS patients younger than 18 years with identified genetic mutations. Data on clinical features, genetic study, therapeutic interventions, and longterm outcomes were reviewed. Results: Five cases of aHUS with an identified genetic mutation were included; all were inaugural cases with the youngest being 4 months old. Complement factor H gene mutation was identified in four patients. Therapeutic plasma exchange was performed for acute management in 4 patients, one of whom also needed acute renal replacement therapy (peritoneal dialysis). All patients went on complete remission, 2 had more than one relapse but only 1 of these progressed to chronic kidney disease during the followup period (median (25th-75th percentile), 136 (43.5-200.5) months). Conclusion: In children, the prognosis of renal function seems to be strongly dependent on the genetic background, thus being crucial to perform genetic study in all aHUS cases. In our cohort, 2 patients presented genetic mutations not previously described. Recent innovations on the genetic field leading to the identification of new mutations has lead to a better understanding of aHUS pathogenesis, but further studies, focusing on the genotype-phenotype correlation, with longer follow-p periods, are needed.